Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sagimet Biosciences Inc. - Series A Common Stock
(NQ:
SGMT
)
5.510
+0.110 (+2.04%)
Streaming Delayed Price
Updated: 3:39 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sagimet Biosciences Inc. - Series A Common Stock
< Previous
1
2
3
Next >
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
October 16, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
October 11, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 01, 2024
Via
Benzinga
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
October 01, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 01, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
September 12, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
September 04, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q2 2024
August 14, 2024
SGMT stock results show that Sagimet Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 14, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
August 01, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
June 10, 2024
Call scheduled on Thursday, June 13, 2024 at 9.30 AM PT / 12:30 PM ET
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
What's Going On With Sagimet Biosciences Stock On Thursday?
June 06, 2024
Sagimet Biosciences shared promising data from its FASCINATE-2 Phase 2b trial of denifanstat at the EASL Congress.
Via
Benzinga
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
June 06, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
June 05, 2024
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment....
Via
Benzinga
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
May 16, 2024
Via
Benzinga
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
May 16, 2024
Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet’s topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024
May 15, 2024
SGMT stock results show that Sagimet Biosciences beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 15, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
May 07, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
May 06, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
April 22, 2024
Sagimet announced positive topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH in January 2024 and plans to initiate Phase 3 trial in the second half of 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
March 27, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 25, 2024
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
March 25, 2024
Via
Benzinga
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
March 25, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
March 25, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
March 17, 2024
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
Via
The Motley Fool
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
February 29, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
February 16, 2024
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright